IFPA 2023 CONFERENCE PRESENTATION AND AWARD FOR INOVIQ CSO

- **Professor Gregory Rice presented the opening address at IFPA 2023 titled *Extracellular vesicle signalling and pregnancy - engineering the opportunities***
- **Prof Rice received the Joan Hunt Senior Award in Placentology, representing the highest distinction of the international placental research community**

Melbourne, Australia, 6 September 2023: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**), a developer of next-generation exosome solutions, is pleased to announce that its Chief Scientific Officer, Professor Gregory Rice, presented the opening address at the International Federation of Placenta Associations (IFPA) Meeting 2023, in Rotorua New Zealand.

Professor Rice presented the opening address entitled *Extracellular vesicle signalling and pregnancy - engineering the opportunities* that discussed the potential of extracellular vesicle (EV) signalling to transform understanding of maternal-fetal communication and afford new opportunities for non-invasive prenatal testing and therapeutic intervention.

Professor Rice's invited presentation comes as part of his receipt of the Joan Hunt Senior Award in Placentology. The award represents the highest distinction of the international placental research community and recognises those who have made a significant contribution to the understanding of placental and reproductive functions in general.

INOVIQ CEO Dr Leearne Hinch said: "This prestigious award and plenary lecture recognises Professor Rice's contribution and leadership, both in the field of placentology and in the broader scientific community. On behalf of the INOVIQ team, I extend my congratulations to Greg for receiving this award. INOVIQ is very fortunate to benefit from his extensive knowledge and expertise across our cancer diagnostic and exosome programs."

Professor Greg Rice is an internationally recognised academic and commercial scientist with more than 30 years' experience in oncology, perinatology, exosome-based research and clinical translational research. He has been instrumental in driving research around the use of exosomes in obstetrical medicine and cancer diagnostics.

For further information about IFPA 2023 and the Joan Hunt Senior Award in Placentology, please visit here. A copy of Professor Rice's oral abstract is appended to this announcement.

- ENDS -

Authorised by the Company Secretary, Mark Edwards.

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-Executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABSTRACT

Extracellular Vesicle Signalling and Pregnancy

Rice G.E.[1,2], Asari K.[1], Nikseresht S.[1], Palma C.[1], Bhuiyan S.[1], Barton S.[1], Khanabdali R.[1]

1.Inoviq Ltd, Notting Hill, Victoria, Australia

2.Centre for Clinical Research, The University of Queensland, Brisbane, Australia

The burgeoning field of extracellular vesicle (EV) signalling has the potential to transform our understanding of maternal-fetal communication and affords new opportunities for non-invasive prenatal testing and therapeutic intervention. EVs have been implicated in implantation, placentation, maternal adaptation to pregnancy, and pregnancy complications, and, from as early as 6 weeks of pregnancy, placental-derived EVs are present in the maternal circulation. Available data support the hypothesis that cells constitutively release discrete populations of EVs of differing biogenesis, composition and bioactivity to maintain homoeostasis and affect intercellular communication. Induction of EV signalling is associated with aberrant cellular metabolism (*e.g.,* glucose and oxygen deprivation and aerobic glycosylation) and manifests as changes in EV concentrations and/or composition. Characterizing such changes affords opportunity to develop more informative diagnostics and efficacious interventions. To effectively leverage EVs as diagnostics (ExoDx) requires: identification of disease-associated biomarkers in specific EV subpopulations; and rapid, reproducible and scalable sample processing. Isolation methods based on physicochemical properties (*i.e.,* density, size, charge) are confounded by co-isolation of particles with similar characteristics. Of promise are methods that resolve EV subpopulations based upon the expression of specific vesicle-surface epitopes and are compatible with robotic liquid-handling platforms. Development of efficacious EV-based therapeutics (ExoTx), similarly, depends upon the expression of vesicle-surface ligands that bind target-cell surface epitopes. Genetic engineering of cells (*e.g.,* MSC, NK cells, T-cells) to release EVs that express cell-targeting ligands and carry prescribed therapeutic payloads is an emerging approach that has several advantages over cell-based therapies, including: low immunogenicity; lack of differentiation capacity; and stability and long-term storage. While ExoDx and ExoTx in reproductive biology remain in a formative phase, enabling technologies are available to: better define EV-based signalling between mother and fetus; its role in normal and complicated pregnancies; and to improve pregnancy outcome for both mother and baby.

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, visit www.inoviq.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and

these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.